Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novocure Ltd NVCR

Healthcare Medical Devices
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and... see more

Recent & Breaking News (NDAQ:NVCR)

INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO

Business Wire March 11, 2024

Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Business Wire February 22, 2024

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

Business Wire January 18, 2024

Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma

Business Wire January 9, 2024

Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update

Business Wire January 8, 2024

Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer

Business Wire January 4, 2024

Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Business Wire December 27, 2023

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability

Business Wire November 28, 2023

Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference

Business Wire November 21, 2023

Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting

Business Wire November 10, 2023

Novocure Reports Third Quarter 2023 Financial Results

Business Wire October 26, 2023

Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023

Business Wire October 15, 2023

Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program

Business Wire October 12, 2023

Novocure to Report Third Quarter 2023 Financial Results

Business Wire October 2, 2023

Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting

Business Wire September 29, 2023

Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer

Business Wire September 8, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the Firm

Accesswire August 30, 2023

Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Business Wire August 29, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the Firm

Newsfile August 28, 2023

Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer

Business Wire August 28, 2023